Life Technologies to Help Identify up to 20,000 Human Remains Found in Libya’s Mass Graves

GLASGOW, Scotland, January 30, 2013/PRNewswire –

Humanitarian project will set up infrastructure, provide expert training, validate and process samples

Life Technologies [http://www.lifetechnologies.com/us/en/home.html ] Corporation (NASDAQ: LIFE) today announced it will provide a complete laboratory solution to identify an estimated 20,000 human remains found in various mass graves in Libya following the uprising of 2011 and to address missing persons cases from the 42-year regime of Muammar Gaddafi. This identification work is expected to take several years.

(Logo: http://photos.prnewswire.com/prnh/20110216/MM49339LOGO)

Life Technologies, a leader in forensic DNA technologies, will provide the infrastructure, including the expertise, training, and the forensic instruments and materials to validate the workflow and process DNA samples through its Dubai-based distributor Integrated Gulf Biosystems (IGB) [http://www.igbiosystems.com/index.aspx].

“It is our hope that many families will find the answers to what happened to their loved ones,” said Peter Silvester, President, Life Technologies, Europe, Middle East & Africa. “By providing the laboratory setup and forensic expertise we will help train Libyan scientists in the very latest instruments, technology and protocols to enable them in their work and help promote reconciliation in Libya.”

Life Technologies will create two separate DNA lines – one geared toward reference samples and the second focusing on processing samples from human remains. Fifty-thousand samples will be processed per year. Human remains samples will be processed using PrepFiler(R) BTA [https://products.appliedbiosystems.com/ab/en/US/adirect/ab?cmd=catNavigate2&catID=608882 ] chemistry optimized to isolate DNA from bones and teeth in combination with AmpFlSTR(R) NGM SElect(TM) PCR Amplification Kit [https://products.appliedbiosystems.com/ab/en/US/adirect/ab?cmd=catNavigate2&catID=606840&tab=DetailInfo ] and MiniFiler(TM) Kit, [http://marketing.appliedbiosystems.com/mk/get/MINIFILER_LANDING ] designed for heavily degraded samples. Reference samples will be processed using direct amplification technology combining Copan NUCLEIC-CARD(TM) [https://products.invitrogen.com/ivgn/product/4473974?ICID=search-product5 ] with NGM SElect(TM) Express [https://products.appliedbiosystems.com/ab/en/US/adirect/ab?cmd=catNavigate2&catID=608993 ] .

The laboratory will utilise the latest generation of genetic analysers and ancillary equipment and will be functionally validated under the quality assurance standards and guidelines required by the ASCLAD-LAB, SWGDAM and ISO 17025. Some training of Libyan scientists will take place in the United States under the direction and supervision of Dr. Arthur Eisenberg [https://profile.hsc.unt.edu/profilesystem/viewprofile.php?pid=10045070&onlyview=1 ], a world renowned forensic scientist, leading up to the lab’s opening in Tripoli.

“The University of North Texas Health Science Center, [http://www.hsc.unt.edu ] with its extensive experience in the identification of missing persons and human decedents, is extremely pleased to partner with Life Technologies in the training of the Libyan forensic scientists to help them complete their mission,” said Dr. Eisenberg, Director of the UNT Center for Human Identification [http://www.hsc.unt.edu/departments/Forensics/Center for Human Identification.cfm ].

The humanitarian project is funded in part by Repsol [http://www.repsolenergy.com/index.html ], a Spanish-based oil company which donated to the Libyan government through its foundation, $2.5 million in 2012 to help establish a state-of-the-art laboratory to identify and generate profiles from human remains and references from associated relatives of missing people.

AmpFlSTR(R) NGM SElect(TM) PCR Amplification Kit, Copan NUCLEIC-CARD(TM), MiniFiler(TM) Kit and NGM SElect(TM) Express are for forensic and paternity use only. PrepFiler(R) BTA is for research use only, not for use in diagnostic procedures.

Life Technologies Corporation [http://www.lifetechnologies.com/us/en/home.html?cid=fl-home%3fCID=fl-home ] (NASDAQ: LIFE [http://www.lifetechnologies.com/us/en/home.html?cid=fl-home%3fCID=fl-home ]) is a global biotechnology company with customers in more than 160 countries using its innovative solutions to solve some of today’s most difficult scientific challenges. Quality and innovation are accessible to every lab with its reliable and easy-to-use solutions spanning the biological spectrum, with more than 50,000 products for agricultural biotechnology, translational research, molecular medicine and diagnostics, stem cell-based therapies, forensics, food safety and animal health. Its systems, reagents and consumables represent some of the most cited brands in scientific research including: Ion Torrent(TM), Applied Biosystems(R), Invitrogen(TM), Gibco(R), Ambion(R), Molecular Probes(R) and Novex(R). Life Technologies employs approximately 10,400 people and upholds its ongoing commitment to innovation with more than 4,000 patents and exclusive licenses. LIFE had sales of $3.7 billion in 2011. Visit us at our website: http://www.lifetechnologies.com.

Life Technologies’ Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

Photo: http://photos.prnewswire.com/prnh/20110216/MM49339LOGO Source: Life Technologies